The authors reflect on changes in Great Britain that were made to research governance in an effort to ensure that clinical trials conducted in the country are safe and effective. They suggest that the changes and regulations developed as a result of the changes are obstructing high quality science. They argue that local governance and indemnity delay the implementation of research studies.
Notes
7678Accession Number: 35536734; Stewart, Paul 1 Stears, Anna 2 Tomlinson, Jeremy W. 3 Brown, Morris J. 4; Email Address: mj.brown@cai.cam.ac.uk; Affiliation: 1: Professor of medicine, University of Birmingham, Birmingham 2: Specialist registrar in clinical pharmacology and endocrinology, Addenbrookes Hospital, Cambridge CB2 2QQ 3: Wellcome trust clinician scientist fellow, Division of Medical Sciences, University of Birmingham 4: Professor of clinical pharmacology, University of Birmingham, Birmingham; Source Info: 11/8/2008, Vol. 337 Issue 7678, p1085; Subject Term: EDITORIALS; Subject Term: MEDICINE -- Research; Subject Term: CLINICAL trials; Subject Term: MANAGEMENT; Subject Term: RESEARCH -- Moral & ethical aspects; Subject Term: HUMAN experimentation in medicine; Subject Term: GOVERNMENT policy; Subject Term: GREAT Britain; NAICS/Industry Codes: 519110 News Syndicates; NAICS/Industry Codes: 541712 Reseach and Development in the Physical, Engineering, and Life Sciences (except Biotechnology); Number of Pages: 3p; Illustrations: 2 Color Photographs; Document Type: Editorial
